1. Home
  2. SFM vs INCY Comparison

SFM vs INCY Comparison

Compare SFM & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprouts Farmers Market Inc.

SFM

Sprouts Farmers Market Inc.

HOLD

Current Price

$85.26

Market Cap

10.9B

ML Signal

HOLD

Logo Incyte Corp.

INCY

Incyte Corp.

HOLD

Current Price

$102.46

Market Cap

17.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SFM
INCY
Founded
2002
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Commercial Physical & Biological Resarch
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
17.0B
IPO Year
2013
1993

Fundamental Metrics

Financial Performance
Metric
SFM
INCY
Price
$85.26
$102.46
Analyst Decision
Buy
Buy
Analyst Count
14
20
Target Price
$138.64
$90.71
AVG Volume (30 Days)
2.2M
2.0M
Earning Date
10-29-2025
10-28-2025
Dividend Yield
N/A
N/A
EPS Growth
49.03
3878.02
EPS
5.15
5.90
Revenue
$8,653,696,000.00
$4,813,105,000.00
Revenue This Year
$15.28
$19.59
Revenue Next Year
$9.86
$10.88
P/E Ratio
$16.61
$17.37
Revenue Growth
16.60
18.09
52 Week Low
$75.75
$53.56
52 Week High
$182.00
$109.28

Technical Indicators

Market Signals
Indicator
SFM
INCY
Relative Strength Index (RSI) 46.56 54.83
Support Level $84.10 $100.55
Resistance Level $86.69 $107.61
Average True Range (ATR) 2.48 2.94
MACD 1.63 -0.98
Stochastic Oscillator 79.65 45.19

Price Performance

Historical Comparison
SFM
INCY

About SFM Sprouts Farmers Market Inc.

Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: